

Around the world of U.S. healthcare in 360 words or less

Center for Healthcare Regulatory Insight

October 15, 2021 | Issue 193

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

Subscribe here 🏑

Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized <u>COVID-19 news for the week in this special supplement</u>.

0



Healthcare regulatory news

CMS announced that <u>68% of 2022 MA plans with prescription coverage</u> (servicing 90% of MA enrollees) will have an overall rating of four stars or higher.

ONC <u>launched a program</u>, building on the U.S. Core Data for Interoperability, to help federal agencies better align and standardize data.

FDA granted <u>Roche's Alzheimer's drug breakthrough therapy</u> designation... FDA approved the first smartwatch for blood oxygen and <u>ECG</u> monitoring... FDA authorized <u>the first e-cigarette</u>, stating it could provide benefits to adult cigarette smokers, including reducing exposure to harmful chemicals... FDA <u>recommended reducing sodium</u> <u>content</u> in commercially processed, packaged, and prepared foods by 12% over the next 2.5 years.

0



Healthcare law and policy news

Robert Califf <u>appears to be frontrunner for nomination</u> by President Biden to return to his former role as FDA Commissioner.

Teva asked the <u>full Federal Circuit court to reconsider a case</u> over generic drug "skinny" labeling.

Walgreens acquired majority stake in <u>VillageMD (\$5.2B)</u> and <u>CareCentrix (\$330M)</u>... Molina Healthcare <u>plans to acquire AgeWell's</u> <u>New York managed long-term-care</u> business (\$110M)... Cigna will <u>divest its life, accident, and supplemental benefits business in seven</u> <u>countries</u> to Chubb... Pacira BioSciences <u>will acquire Flexion</u> <u>Therapeutics</u> (\$427.5M)... Best Buy <u>will acquire Current Health</u>... Headspace and Ginger <u>finalized their merger</u>.

Pfizer will <u>offer warranties for a lung cancer treatment and refund the</u> <u>cost</u> to any patient and health plan if the medication fails to work within the first three months.

USPSTF issued draft guidance advising against adults age 60 and older who do not have a history of heart disease or stroke taking daily low-dose aspirin to prevent heart attacks... CDC recorded over 96,000 drug overdose deaths in the 12-month period ending in March, up 30% from the preceding year.

Urban Institute estimated <u>nearly 1 million uninsured children and</u> <u>parents could get insurance coverage</u> if Congress made temporary, enhanced income-based ACA subsidies permanent... RWJF reported the <u>obesity rate among US children ages 2 to 19 increased from 19.3%</u> <u>in 2019 to 22.4%</u> in 2020... IHI reported <u>58% of health systems</u> <u>identified health equity as a top priority</u>, up from 25% in 2019... A KFF poll found <u>83% of respondents, including 76% of Republicans, favor</u> allowing the federal government to negotiate prescription drug prices. 0

Questions or comments, please send to <u>us-</u> <u>hcinsight@kpmg.com</u>.

Succeeding in the new reality

Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.

kpmg.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



COVID-19 News Supplement

Center for Healthcare Regulatory Insight



COVID-19 by the Numbers

There have now been <u>roughly 50.5 million confirmed COVID-19 cases</u> in the US, with a death toll over 720,000... The country is <u>averaging approximately 91,000 new cases per day</u> over the past week, down 19% over the past two weeks; however deaths per day remained roughly unchanged at 1,900.

405 million COVID-19 <u>vaccine doses have been administered</u> in the US (roughly 835,000/day over the past week)... Roughly 218 million Americans (<u>76.8% of Americans 12 and older</u>) have received at least one COVID-19 vaccine dose; 188 million Americans are fully vaccinated (66.4% of Americans 12 and older); 9.3 million Americans have received a booster dose... Axios reported that <u>more Americans are getting booster doses per day</u> than are getting first doses.

Executive and Administrative Action

The Biden Administration will <u>allow non-essential travelers who have been fully vaccinated to enter the</u> <u>US</u> via land or ferry crossings from Canada or Mexico.

The Biden Administration is <u>moving pandemic tracking data (HHS Protect) back over to CDC</u>, following the Trump Administration moving the system under management of the HHS Office of the Chief Information Officer.

Healthcare Regulatory News

OMB <u>began review of an OSHA rule</u> requiring many private sector companies to <u>mandate employee</u> <u>vaccinations or regular testing</u>.

Healthcare Law, Business, and Policy News

Abbott Molecular is recalling two COVID-19 laboratory test kits due to risk of false-positive results.

Premier estimated that hospitals have <u>spent more than \$3 billion on personal protective equipment</u> since the pandemic began.

PointClickCare <u>announced a contract to provide the CDC</u> with comprehensive, deidentified patient data for residents of long-term and post-acute care facilities, to assess the impact of COVID-19 and other threats on long-term care facility residents.

An <u>Axios/Ipsos survey found</u> that 42% of Americans trust President Biden a great deal or a fair amount to provide them with accurate information on COVID-19, down 16 percentage points from Inauguration day; meanwhile, 22% report that they've returned to pre-COVID life, down from 28% in June... A National Association of School Nurses-Covid-19 Vaccine Education and Equity Project survey found that

two-thirds of parents are likely to vaccinate their five to 11 year old children once a vaccine is authorized.

Surveillance, Testing, and Treatment

FDA's Vaccines and Related Biological Products Advisory Committee <u>voted unanimously in support of</u> <u>authorizing Moderna's COVID-19 vaccine booster</u> to people 65 and older, those 18 to 64 with risk factors for severe COVID-19, and those whose jobs put them at high risk for serious complications... FDA documents prior to the meeting <u>laid out arguments for authorizing a Moderna booster</u>, while also noting that <u>data so far is unclear</u> on whether a booster is necessary.

The Advisory Committee will <u>meet today to consider booster shots of Johnson & Johnson's</u> (J&J) COVID-19 vaccines and to discuss mixing and matching doses for different manufacturers... J&J is requesting FDA to authorize its COVID-19 vaccine booster with <u>varying timing of a second dose</u> from two to six months based on the patient's occupation and health status... FDA data show that protection conferred by J&J's vaccine against moderate to severe COVID-19 decreases over time, from <u>72% effectiveness two</u> to four weeks post-vaccination to 42% nearly four months after initial shot and that a <u>booster showed</u> signs of bolstering immunity... NIH data show that people who got the J&J vaccine have a <u>stronger</u> neutralizing antibody response if they receive an mRNA booster instead of a second J&J shot.

CDC's Advisory Committee on Immunization Practices will <u>meet October 20 and 21</u> to discuss booster shots of the Moderna and J&J vaccines and meet November 2 and 3 to evaluate vaccines for children under age 12.

Moderna <u>does not plan to share the formula</u> for its COVID-19 vaccine because company executives believe increasing its own production is a better way to increase global supply... White House Chief Science Officer for COVID-19 response, David Kessler, <u>strongly criticized Moderna for not providing</u> <u>additional vaccine doses</u> to support global supply and threatened more aggressive government action if the company does not "step up."

CureVac will <u>stop working on its experimental COVID-19 vaccine</u> and instead focus on a next generation vaccine aimed at variants and boosting protection.

Merck <u>filed for FDA emergency use authorization</u> for its oral COVID-19 antiviral molnupiravir... ... FDA's Antimicrobial Drugs Advisory Committee will <u>meet November 30 to discuss possible emergency use</u> <u>authorization</u> for the drug... Merck plans to <u>double production capacity next year</u> for the antiviral pill and make cheaper versions through licensing deals with eight generic manufacturers.

AstraZeneca reported that its <u>injected antibody cocktail reduced the risk</u> of severe COVID-19 or death by 50% in non-hospitalized patients who have had symptoms for seven days or less.... European Medicines Agency <u>began review of the injectable</u> antibody therapy.

The US government will <u>manage distribution of GlaxoSmithKline-Vir Biotechnology's monoclonal</u> <u>antibody</u>.

The World Health Organization <u>announced a proposed list of 26 experts</u> for its new Scientific Advisory Group for the Origins of Novel Pathogens to explore the <u>origins of high-threat pathogens, including</u> <u>COVID-19</u>.